Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.
Future Oncol
; 20(20): 1427-1434, 2024.
Article
en En
| MEDLINE
| ID: mdl-38864297
ABSTRACT
Aim:
There is limited data available regarding the comparison of Sacituzumab govitecan (SG) vs. chemotherapy in metastatic breast cancer patients.Materials &methods:
We performed a systematic review and meta-analysis aimed to assess the safety profile of SG vs. chemotherapy for metastatic breast cancer (mBC) clinical trials.Results:
The pooled odds ratio for outcomes such as grade 3-4 and all grade neutropenia, leukopenia, anemia and other non-hematological adverse events showed a higher risk for patients receiving SG. No statistically significant differences were reported in terms of grade 3-4 fatigue, all grade nausea, febrile neutropenia and treatment discontinuation due to adverse events.Conclusion:
Our data, coupled with a statistically and clinically meaningful survival benefit, support the use of SG for mBC.
[Box see text].
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Camptotecina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Anticuerpos Monoclonales Humanizados
Límite:
Female
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article